AbbVie’s subsidiary Allergan has announced the availability of FDA-approved eye drop, VUITY (pilocarpine HCl ophthalmic solution) 1.25%, by prescription in pharmacies across the US. VUITY is a once-a-day
Prestige BioPharma and Dr. Reddy’s Laboratories have signed a binding agreement to commercialise the former’s trastuzumab (HD201) biosimilar in select Latin America and Southeast Asian countries. Trastuzumab (HD201),
By working with both Roche and Genentech’s R&D units, Recursion will tap technology-enabled drug discovery through its Operating System (OS) to more quickly identify novel targets and then
Canadian biopharmaceutical firm Arbutus Biopharma has identified many molecules that can inhibit the SARS-CoV-2 nsp5 main protease (Mpro), achieving its first milestone under Covid-19 discovery research and license
This deal is part of Merck’s commitment to make the drug available across the globe, following approval for use by regulatory bodies. Merck, in collaboration with Ridgeback Biotherapeutics,
The European Medicines Agency (EMA) has accepted to review Sanofi’s marketing authorization application (MAA) for olipudase alfa to treat acid sphingomyelinase deficiency (ASMD). An investigational enzyme replacement therapy,
Julphar is a pharmaceutical company based in the UAE and has presence in the MENA (Middle East North Africa) region. It will secure exclusive rights to produce and
Merck’s anti-PD-1 therapy, Keytruda, has obtained approval from the US Food and Drug Administration (FDA) as an adjuvant therapy for stage IIB or IIC melanoma patients aged 12
Valneva stated that it is now focused on securing regulatory approvals for VLA2001 after the positive results from the Phase III trial. The firm also added that it
Financial details of the deal have not been disclosed. This deal is part of Sanofi’s strategy to explore growth opportunities and build a vaccines pipeline. The transaction will
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.